Inviragen

About Inviragen

Inviragen, Inc. operated as a biopharmaceutical company with a sharp focus on developing vaccines for emerging infectious diseases that affect populations globally. Founded in 2005 by Dr. Dan Stinchcomb and Dr. Jorge Osorio, the company established its headquarters in Fort Collins, Colorado, with additional facilities in Madison, Wisconsin, and a significant vaccine development center in Singapore. The founders brought extensive experience to the venture; Dr. Stinchcomb, who served as CEO, had a distinguished career in life sciences, including leadership roles at Synergen Inc., Ribozyme Pharmaceuticals, and Heska Corp., after receiving his PhD from Stanford and a BA from Harvard. Dr. Joseph Santangelo also played a key role, founding a company in Singapore in 2005 to develop treatments for diseases endemic to Asia, which later merged with Inviragen in 2009.

The company's business model was centered on the research and clinical development of vaccines for diseases with significant unmet medical needs, particularly in developing countries. Inviragen's primary product candidate was DENVax, a tetravalent (four-strain) recombinant viral vaccine for the prevention of dengue fever, a mosquito-borne illness threatening nearly half of the world's population. This vaccine, licensed from the U.S. Centers for Disease Control and Prevention (CDC), was designed to provide broad protection and advanced to Phase 2 clinical trials. The company's pipeline also included a vaccine for hand, foot, and mouth disease (HFMD), which had completed Phase 1 testing, and preclinical programs for chikungunya and Japanese encephalitis.

A pivotal moment in Inviragen's history occurred in May 2013 when it was acquired by Takeda Pharmaceutical Company Limited. The acquisition agreement included an upfront payment of $35 million with potential future payments of up to $215 million tied to development and commercial milestones. This strategic acquisition was a key step in Takeda's plan to build a world-class global vaccine business, integrating Inviragen's pipeline and its team of approximately 50 employees into Takeda's Vaccine Business Division. The deal provided Takeda with Inviragen's promising dengue vaccine candidate and its research capabilities, particularly the development center in Singapore, a region heavily impacted by the diseases Inviragen targeted.